| Kamran Safdar, MD | |
|
222 Piedmont Ave, Cincinnati, OH 45219-4231 | |
| (513) 475-7505 | |
| (513) 475-7355 |
| Full Name | Kamran Safdar |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 34 Years |
| Location | 222 Piedmont Ave, Cincinnati, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538239439 | NPI | - | NPPES |
| 0462231 | Medicaid | OH | |
| 2565399 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 35 129484 (Ohio) | Secondary |
| 207RT0003X | Internal Medicine - Transplant Hepatology | 35129484 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Cincinnati Medical Center, Llc | Cincinnati, OH | Hospital |
| West Chester Hospital | West chester, OH | Hospital |
| Bethesda North | Cincinnati, OH | Hospital |
| Good Samaritan Hospital | Cincinnati, OH | Hospital |
| Mercy Health - Clermont Hospital | Batavia, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trihealth H Llc | 1850570458 | 668 |
| University Of Cincinnati Physicians Company Llc | 2264344480 | 1339 |
News Archive
The Ontario Long Term Care Association (OLTCA) is delighted to congratulate two of its members on being nationally recognized for the levels of excellence they have achieved in developing quality relationships and processes within their organizations.
OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.
› Verified 5 days ago
| Entity Name | University Of Cincinnati Physicians Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801840434 PECOS PAC ID: 2264344480 Enrollment ID: O20031105000123 |
News Archive
The Ontario Long Term Care Association (OLTCA) is delighted to congratulate two of its members on being nationally recognized for the levels of excellence they have achieved in developing quality relationships and processes within their organizations.
OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.
› Verified 5 days ago
| Entity Name | Trihealth G Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295862944 PECOS PAC ID: 0749222651 Enrollment ID: O20050601000358 |
News Archive
The Ontario Long Term Care Association (OLTCA) is delighted to congratulate two of its members on being nationally recognized for the levels of excellence they have achieved in developing quality relationships and processes within their organizations.
OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.
› Verified 5 days ago
| Entity Name | Trihealth H Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811215742 PECOS PAC ID: 1850570458 Enrollment ID: O20110128000356 |
News Archive
The Ontario Long Term Care Association (OLTCA) is delighted to congratulate two of its members on being nationally recognized for the levels of excellence they have achieved in developing quality relationships and processes within their organizations.
OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kamran Safdar, MD Po Box 636256, Central Credentialing, Cincinnati, OH 45263-6256 Ph: (513) 585-5507 | Kamran Safdar, MD 222 Piedmont Ave, Cincinnati, OH 45219-4231 Ph: (513) 475-7505 |
News Archive
The Ontario Long Term Care Association (OLTCA) is delighted to congratulate two of its members on being nationally recognized for the levels of excellence they have achieved in developing quality relationships and processes within their organizations.
OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that additional evaluation of a previous Phase I trial provided further evidence that a DNA plasmid encoded to produce IL-12 delivered by electroporation into melanoma lesions induces responses to known and novel antigens, resulting in regression of local treated lesions as well as distant untreated lesions.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
New data presented at recent neurological congresses and summarized at the IDS indicate that patients treated with XEOMIN for cervical dystonia or blepharospasm (involuntary closing of the eyelids) experienced long-term sustained efficacy with a favorable safety profile in studies of up to 121 and 88 weeks duration, respectively.
› Verified 5 days ago
Moises Arturo Huaman Joo, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 234 Goodman Street, Cincinnati, OH 45219 Phone: 513-584-6977 Fax: 513-584-4281 | |
Dr. Kiranmayee Lanka, M.D., M.P.H Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2123 Auburn Ave, Suite 401, Cincinnati, OH 45219 Phone: 513-241-5489 Fax: 513-241-5490 | |
Dr. Saurabh Chandra, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 234 Goodman St, Cincinnati, OH 45219 Phone: 513-558-1000 | |
Gretchen Suarez, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10500 Montgomery Rd, Cincinnati, OH 45242 Phone: 513-865-2246 Fax: 513-865-5596 | |
Dr. Andrew Michael Espinal, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4777 E Galbraith Rd, Cincinnati, OH 45236 Phone: 513-686-3000 | |
Sorina M Macavei, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 463 Ohio Pike, Suite 300, Cincinnati, OH 45255 Phone: 513-528-5600 Fax: 513-528-9716 | |
Helen K Koselka, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3219 Clifton Ave, Suite 100, Cincinnati, OH 45220 Phone: 513-528-5600 Fax: 513-528-9716 |